

The text in English is an unofficial translation of the Swedish original wording. If there are differences between the English translation and the Swedish original, the Swedish text takes precedence.

THE NOMINATION COMMITTEE'S PROPOSALS FOR THE AGM 2023

The Nomination Committee for the AGM 2023 comprises the following members: David Sundin, representing Corespring New Technology AB (Chairman of the Nomination Committee), Jari Pulkkinen, representing the "Consortium", Candice Jung, representing PharmaResearch Co. Ltd., and Marianne Dicander Alexandersson, Chairman of the Board in Promore Pharma AB (publ).

The Nomination Committee presents the following proposals for the AGM 2023.

Election of Chair of the meeting

The Nomination Committee proposes that Anders Björnsson, Advokaterna Liman & Partners, or if he is prevented from attending, the person the Nomination Committee proposes in his place, be elected to chair the meeting.

Determination of the number of directors, alternate directors and auditor and alternate auditor

The Nomination Committee proposes that the Board shall be composed of five directors, with no alternates, for the period until the next AGM. The Nomination Committee proposes that the company will have one auditor and no alternate.

Determination of the fees for the directors and for the auditor

The Nomination Committee proposes that the fees for the directors will be paid as follows. The Chairman of the Board will receive SEK 300,000 and the other directors will receive SEK 150,000 each.

Fees will be paid to the auditor on current accounts.

Election of directors, Chairman of the Board and auditor, and, when applicable, alternate directors and an alternate auditor

The Nomination Committee proposes re-election of Marianne Dicander Alexandersson, Hans-Peter Ostler, Göran Linder, Kerstin Valinder Strinnholm and Candice Jung. It is proposed that Marianne Dicander Alexandersson be re-elected Chairman of the Board.

Information about the proposed directors is available on the company's website:

www.promorepharma.com.

The Nomination Committee proposes that the registered audit company Finnhammars Revisionsbyrå AB be re-appointed auditor. Finnhammars Revisionsbyrå AB has given notice that, if the Nomination Committee's proposal for auditor is adopted at the meeting, Per-Olov Strand will be the person appointed to have main responsibility for the audit.

The text in English is an unofficial translation of the Swedish original wording. If there are differences between the English translation and the Swedish original, the Swedish text takes precedence.

REASONED STATEMENT BY THE NOMINATION COMMITTEE

The Nomination Committee has carried out an evaluation of the present Board's work as a basis for its proposals.

In this evaluation the Nomination Committee has found that the present Board's work was satisfying and well-functioning, that the directors are committed to their work, that they have been well prepared before Board meetings, that the attendance at Board meetings has been very high, and that the Chairman of the Board has presided the work efficiently.

In the opinion of the Nomination Committee the current Board has a relevant composition, given the company's business and development stage, and that the proposed directors possess an extensive competence with solid industrial as well as financial knowledge with an international experience. The Nomination Committee will, when recruiting candidates in the future, continue the search for suitable candidates representing both genders.

Solna in May 2023

Nomination Committee for Promore Pharma AB (publ)